Search clinical trials for: Bendamustine hydrochloride injection

Total 16497 results

Jiangsu Simcere Pharmaceutical Co., Ltd.

Completed

Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection

Indolent B-Cell Non-Hodgkin's Lymphomas

China
University of California, Davis
Novartis

Completed

Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer

Multiple Myeloma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Adult Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Untreated Adult Acute Myeloid... and other conditions

United States
Beth Christian

Completed

Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Recurrent Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Lymphocyte Predominant Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin Lymphoma | Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma

United States
Shandong Lanjin Pharmaceuticals Co.,Ltd

Unknown

Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Neoplasms | Leukemia | Chronic Lymphocytic Leukemia

China
University Hospital Tuebingen
Arbeitsgemeinschaft fur Internistische Onkologie; German Sarcoma Group

Completed

Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS)

Sarcoma, Soft Tissue

Germany
Charite University, Berlin, Germany
ribosepharm GmbH

Unknown

Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)

Recurrent Small Cell Lung Cancer

Germany
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Adult Hodgkin Lymphoma | Recurrent Adult T-cell Leukemia/Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Withdrawn

Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma

United States
University of Arizona
Cephalon

Completed

Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer

Ovarian Cancer

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
University of Washington
National Cancer Institute (NCI); National Comprehensive Cancer Network

Completed

Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma

Adult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Neoplasm

United States
SymBio Pharmaceuticals

Completed

Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

Japan
Medical University of Vienna

Not yet recruiting

Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

Mantle-cell Lymphoma
Meir Medical Center
Assuta Ashdod Hospital; Rabin Medical Center; Tel-Aviv Sourasky Medical Center; Ziv Medical Center

Recruiting

Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status (FLMRD)

Follicular Lymphoma

Israel
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Lung Cancer

United States
SymBio Pharmaceuticals

Completed

A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Japan
Novartis Pharmaceuticals

Completed

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukemia (CLL) | Leukaemia, Lymphocytic, Chronic

United States, Belgium, Italy, Greece, Russian Federation, Spain, Poland, Czech Republic
Prof. Dr. Wolfgang Hiddemann
Hoffmann-La Roche; Mundipharma Research GmbH & Co KG

Completed

First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years (GABe2016)

Indolent Non-hodgkin Lymphoma

Germany
Cephalon

Completed

Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Ruijin Hospital

Recruiting

A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma

Lymphoma, Mantle-Cell

China
SymBio Pharmaceuticals

Completed

SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors

Advanced Solid Tumor

Japan
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment

Non-Hodgkin Lymphoma

China
Cephalon

Completed

Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin's Lymphoma (NHL)

United States, Belgium, Israel
NYU Langone Health
Cephalon

Terminated

Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma

Multiple Myeloma

United States
M.D. Anderson Cancer Center

Withdrawn

Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)

Lymphoma | Leukemia
Mayo Clinic

Completed

Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Refractory Multiple Myeloma

United States
M.D. Anderson Cancer Center
Cephalon

Terminated

Bendamustine in Acute Leukemia and MDS

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome

United States
Cephalon

Completed

Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy

Malignancy

Netherlands
InnoCare Pharma Inc.

Not yet recruiting

A Global Phase 3 Study of Orelabrutinib+BR vs.BR in Pts With TN MCL

Mantle Cell Lymphoma
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia

Leukemia

Israel, United States, Australia, Belarus, Brazil, Canada, Korea, Republic of, Mexico, New Zealand, Poland, Russian Federation, Singapore
Memorial Sloan Kettering Cancer Center
Cephalon

Completed

Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma

Lymphoma | Hodgkin's Disease

United States
H. Lee Moffitt Cancer Center and Research Institute
National Comprehensive Cancer Network; Cephalon

Terminated

Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors

Brain Metastases

United States
Yale University

Withdrawn

A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)

Hematopoietic/Lymphoid Cancer | Infectious Mononucleosis | PTLD | Lymphoid Tumor | Plasmacytic Hyperplasia PTLD | Florid Follicular Hyperplasia PTLD | Polymorphic PTLD | Monomorphic PTLD | Classical Hodgkin Lymphoma Type PTLD

United States
Kami Maddocks, MD
Pharmacyclics LLC.

Active, not recruiting

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent... and other conditions

United States
University of Washington
National Cancer Institute (NCI)

Completed

Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
German Breast Group

Completed

A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer (RiTa)

Metastatic Breast Cancer
UNC Lineberger Comprehensive Cancer Center
Cephalon

Completed

Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma

Lymphoma | Diffuse Large B-Cell Lymphoma | Lymphoma, Diffuse Large-Cell | Diffuse Large-Cell Lymphoma

United States
Cairo University

Recruiting

Anti-Plaque and Anti-Gingivitis Effects of Moringa Plant Extract and Fluoride Toothpastes

Oral Disease

Egypt
French Innovative Leukemia Organisation
Mundipharma Pte Ltd.

Completed

Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma (BENTLY)

T-cell Lymphoma

France
WiSP Wissenschaftlicher Service Pharma GmbH
Mundipharma Research GmbH & Co KG; Klinikum Leverkusen gGmbH; ribosepharm GmbH

Completed

Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

Germany
Eagle Pharmaceuticals, Inc.

Completed

A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients

Cancer Which Has Either Progressed or Relapsed After Standard Therapy, or for Which no Curative or Standard Therapy is Appropriate

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

GIMEMA CLL0809 Study (BendOfa) (BendOfa)

Patients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; or | Patients With CLL Refractory (SD, PD or CR/PR < 6 Months) Following no More Than Two Prior Treatment Lines

Italy
Shandong Lanjin Pharmaceuticals Co.,Ltd

Unknown

Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma by Clinical Course

China
German CLL Study Group
Gilead Sciences; Novartis Pharmaceuticals

Completed

Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)

Chronic Lymphocytic Leukemia

Germany
Samsung Medical Center

Unknown

Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL)

Mantle Cell Lymphoma

Korea, Republic of
Novartis Pharmaceuticals

Completed

Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma

Cancer

United States
SCRI Development Innovations, LLC
GlaxoSmithKline; Novartis; Cephalon

Completed

Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy

Diffuse Large B-Cell Lymphoma

United States
Fondazione Italiana Linfomi ONLUS

Completed

A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma (IIL INFL09)

Non-Hodgkin's Lymphoma | Indolent Non-follicular

Italy

Search clinical trials for: Bendamustine hydrochloride injection

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations